Non-cystic fibrosis bronchiectasis ("bronchiectasis") is a chronic slowly progressive inflammatory pulmonary disease that is characterized by airway inflammation and excess sputum production. The prevalence of this orphan disease increased 8.7% per year between 2000 and 2007, affecting 100,000 to 200,000 patients in the US Medicare population. 1 Associated infections (eg, nontuberculous mycobacteria [NTM] , Pseudomonas aeruginosa, Haemophilus influenzae) worsen inflammation and damage to lungs. 2 The goals of treatment are to improve symptoms, reduce airway inflammation, limit further bronchiectasis progression, and prevent infections. There are no US guidelines for the selection of therapies. The British Thoracic Society published guidelines in 2010 highlighting a lack of evidence for safety and effectiveness of chronic pharmacotherapy. 3 Drugs with anti-inflammatory properties, for example, corticosteroids, have been studied in COPD and other lung diseases, but their safety and effectiveness in bronchiectasis remains unproven. 4 Macrolides (eg, erythromycin, azithromycin) have both antimicrobial and immunomodulatory properties. 5 Historically, inhaled antibiotics are prescribed primarily to control P aeruginosa in patients with frequent exacerbations. 3 What is unknown is how many patients with bronchiectasis are taking inhaled corticosteroids (ICSs), macrolide monotherapy, or inhaled antibiotics in the United States or elsewhere. To provide background for a proposed comparative effectiveness and safety study in US patients, we sought to describe the current and past use of ICSs, oral macrolides, and inhaled antibiotics in patients with bronchiectasis and explore patient characteristics associated with each therapy.
Methods
Our first data source was an anonymous electronic 20-question SurveyMonkey survey (e-Appendix 1) developed by several study authors. The survey link was e-mailed by NTM Info & Research (NTMir), a nonprofit NTM patient advocacy organization, to 2,000 patients in December 2013. Responses were collected through January 2014. Patients self-identified as having bronchiectasis. Patients reported whether they had ever taken or were currently taking inhaled tobramycin, oral azithromycin for NTM treatment, oral azithromycin for other infections or exacerbation prevention, oral steroids, or ICSs with or without long-acting beta agonists (LABA). We also asked patients to estimate the cumulative lifetime duration of treatment with azithromycin or ICSs as < 4 weeks, 4 weeks to < 1 year, or 1 year or longer. The survey was anonymous and was conducted as "preparatory to research."
The second data source was the national Bronchiectasis and NTM Research Registry (BRR), managed by the COPD Foundation. 6 The BRR is actively enrolling from 13 sites and includes detailed clinical and microbiological data for > 2,000 patients with bronchiectasis or patients who meet the American Thoracic Society/Infectious Diseases Society of America 2007 case criteria for NTM disease. 7 For this analysis, any patient with a history of or current NTM isolation was classified as having NTM infection ("NTM"), regardless of whether or not they met American Thoracic Society/Infectious Diseases Society of America disease criteria. The BRR collects data from chart review, including patient demographics, current pharmacotherapy, COPD or asthma diagnosis, history of P. aeruginosa or Staphylococcus aureus isolation, exacerbation in prior 2 years, or hospitalized exacerbation in prior 2 years. BRR data captured current "suppressive" macrolide and inhaled antibiotic therapy, indicating use other than for acute exacerbations. Oral steroids were marked as "continuous" or "intermittent" and combined into a single variable to describe current use. The BRR was approved by each site's institutional review board.
First, we described the characteristics of the survey and registry populations. For both data sets, we reported the proportion of patients taking each class of therapy, stratified by NTM in BRR patients. Next, in patients without NTM in the BRR, we separately compared "current users" of (1) inhaled corticosteroids, (2) macrolides, and (3) inhaled antibiotics to "nonusers" of each group. We performed statistical comparisons using the c characteristics, with P < .20 in unadjusted logistic regression analysis. Several variables were categorized for logistic regression models: age ($ 65 years or < 65 years), exacerbation history (none, nonhospitalized only, or any hospitalized exacerbation in prior 2 years), and FEV 1 % predicted ($ 80%, 50 to < 80%, and < 50%). All statistical analysis was conducted in SAS, version 9.4 (SAS Institute).
Results

NTMir Survey Responders
The response from the NTMir e-mail included 511 self-identified patients with bronchiectasis (response rate, 26%) ( Table 1 ). There was no information available on nonresponders. The median age of respondents was 67 years; most (420 [93%]) were women. Most (392 [77%]) reported a current diagnosis of NTM infection, and 99 (19%) reported COPD or current P aeruginosa infection or colonization.
NTMir Survey Self-Reported Therapy
Overall, 282 patients (55%) reported ICS use in the past or present, including 239 cases (85%) in combination with LABA. Among those who reported the use of ICSs, 171 (61%) reported a cumulative duration of > 1 year total, and 150 (53%) reported current use of ICSs. High rates of current or past antibiotic use were reported, including 203 (40%) taking azithromycin but not for NTM, and 78 (15%) taking inhaled tobramycin. Concurrent ICS and In univariate analysis, the prevalence of asthma was more than twice as high in patients taking ICSs (46% vs 21% not taking ICSs; P < .0001) as was P aeruginosa isolation (40% vs 23%; P < .0001) ( Table 2 ). The final multivariate model included age category, sex, COPD, asthma, S aureus, P aeruginosa, exacerbation history category, and FEV 1 % predicted category. In multivariate analysis ( Patients taking macrolides were younger (median age, 62.9 years vs 68.8 years among those not taking macrolides; P ¼ .006) and had more prior hospitalized exacerbations (36% vs 23%; P ¼ .006) and P aeruginosa isolation (44% vs 28%; P ¼ .002) ( Table 2) . The final multivariate model consisted of age category, S aureus, P aeruginosa, exacerbation history category, and FEV 1 % predicted category (Table 3) . In multivariate analysis, P aeruginosa isolation (aOR, 2.2; 95% CI, 1.4-3.4) was significantly associated with an increased odds of taking oral macrolides therapy, whereas age > 65 years (a OR, 0.6; 95% CI, 0.4-0.9) was significantly associated with a decreased odds of taking macrolides.
Factors Associated With Current Inhaled Antibiotic Therapy in BRR Patients Without NTM
Patients taking inhaled antibiotics had the highest rates of P aeruginosa isolation (69% vs 25% in those not taking inhaled antibiotics; P < .0001) and prior exacerbations (87% vs 66%; P ¼ .0002) and hospitalized exacerbations (39% vs 24%; P ¼ .005) ( Table 2) . The final multivariate model included sex, asthma, P aeruginosa, exacerbation history, and lung function. In multivariate analysis (Table 3) , P aeruginosa isolation (aOR, 5.9; 95% CI, 3.4-10.5) and prior hospitalization for exacerbation (aOR, 2.6; 95% CI, 1.1-5.9) remained significantly associated with inhaled antibiotic therapy.
Discussion
We observed high rates of ICS use in patients with bronchiectasis despite the lack of evidence to support its use. There was modest use of macrolides and inhaled antibiotics, which was better supported by clinical trial results in patients with bronchiectasis. The use of all three types of pharmacotherapy was associated with a history of P aeruginosa isolation.
ICSs, alone or with LABA, are recommended for longterm treatment of severe asthma and in patients with advanced COPD. 8, 9 Although the disease mechanisms are different, the use of ICSs in patients with COPD and the inflammatory nature of bronchiectasis has likely led to the use of ICSs for bronchiectasis despite a lack of evidence supporting its use in patients with bronchiectasis. In the BRR, only 57% of patients taking ICSs had either a COPD or asthma diagnosis. Asthma remained significantly associated with ICS use in multivariate analysis, whereas COPD did not. For patients with COPD without bronchiectasis, the benefits of ICSs include fewer exacerbations and improved lung function, although there is an increased risk of serious pneumonia. 10 In a large Danish cohort study, the observed relative risk of serious pneumonia in patients with COPD was 1.69 (95% CI, 1.63-1.75) comparing current ICS users to chestjournal.org Approximately 15% of patients were using macrolides chronically; < 31% received "long-term macrolide treatment" in a report from a five-country European cohort of 1,145 patients with bronchiectasis. 12 Evidence supporting macrolide antibiotic use for 6 to 12 months was observed in three placebo-controlled randomized clinical trials of patients with bronchiectasis published in 2012 and 2013. [13] [14] [15] All three studies showed fewer respiratory exacerbations but limited or no improvement in lung function. Given the high rates of NTM found in BRR patients with bronchiectasis, monotherapy with macrolides to prevent exacerbations should be considered only after screening for NTM. 16 Macrolide-resistant NTM is associated with poorer outcomes. 17 Additional trials are needed to evaluate the potential benefit of macrolides regarding prevention of NTM infection as well as to quantify the risks of macrolide resistance developing in NTM. In addition, the rare but serious short-term risks of sudden cardiac arrest should be considered. 18 Ten percent of BRR patients without NTM (22% of those with P aeruginosa isolation) were taking inhaled antibiotics. A similar proportion (8%) overall but a higher proportion (36%) among those with Pseudomonas infection in the previously mentioned European cohort had a history of "long-term inhaled antibiotic treatment." 12 There is moderate evidence to support the use of inhaled antibiotics to reduce sputum bacterial load and the risk of exacerbations. 19 Documented risks of inhaled antibiotics include bronchospasm, ototoxicity, and renal failure. According to BTS guidelines, inhaled antibiotics should be considered in patients with P aeruginosa colonization who experience 3þ exacerbations per year. 3 Appropriately, prior hospitalized exacerbations and P aeruginosa isolation were associated with the use of inhaled antibiotics in our study. Of note, a history of P aeruginosa isolation was the only factor independently associated with all three categories of therapy. P aeruginosa colonization is associated with worse outcomes in patients with bronchiectasis 12, [20] [21] [22] ; thus physicians may have prescribed ICSs or macrolides to minimize associated inflammation.
Strengths of our study include the use of two national data sources. We captured "suppressive" macrolide use from the BRR and the duration of ICS use in NTMir patients. Limitations include a low NTMir response rate, although NTMir members have a primary diagnosis or history of NTM infection and not all have underlying bronchiectasis. BRR patients are enrolled at specialty clinics and may not represent treatment practices in the community. In addition, we are missing details regarding dose, formulation, and duration of the most recent episode of use to further describe practice patterns in BRR patients. Other factors associated with ICS use, such as symptoms that may drive treatment choice, were not evaluated in this analysis but should be explored.
Conclusions
In conclusion, we observed the high rates of use of ICS despite unproven clinical efficacy and risks of use. Additional evidence is needed so that clinicians and patients can better weigh the risks and benefits and determine the optimal duration of pharmacotherapy for bronchiectasis.
